Search
Idarucizumab
go.drugbank.com/drugs/DB09264ApprovedAs a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease
Anthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47526] It is considered one of the most likely agents to be used in a biological attack.
Toripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalOne mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition
Valaciclovir
go.drugbank.com/drugs/DB00577ApprovedInvestigationalOne major use of valacyclovir is the treatment of genital herpes episodes or outbreaks.
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigational[L43402] The pharmacological profile of chloroprocaine is characterized by a short latency and duration, similar to the one observed with [lidocaine].
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tuca...
Niacinamide ascorbate
go.drugbank.com/drugs/DB14486ApprovedNutraceuticalWithdrawnMixtures: Se-Natal OneInebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOS...
Darunavir
go.drugbank.com/drugs/DB01264ApprovedInvestigationalDarunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to...
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor...